	US 12,312,639 B2
	Alzheimer's disease personalized medicine
Janos Redei, San Francisco, CA (US)
Assigned to i2Dx, Inc., San Francisco, CA (US)
Filed by i2Dx, Inc., San Francisco, CA (US)
Filed on Jul. 16, 2021, as Appl. No. 17/378,487.
Application 17/378,487 is a division of application No. 15/919,666, filed on Mar. 13, 2018, granted, now 11,089,959.
Application 15/919,666 is a continuation in part of application No. 15/714,984, filed on Sep. 25, 2017, granted, now 10,660,522, issued on May 26, 2020.
Application 15/714,984 is a continuation of application No. 13/842,004, filed on Mar. 15, 2013, granted, now 9,782,075, issued on Oct. 10, 2017.
Prior Publication US 2021/0338080 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

1 Claim

1. A method for detection of at least one single nucleotide polymorphism (SNP) in a human subject from assaying a combination of SNPs, comprising:

a) obtaining a nucleic acid sample from said human subject;

b) genotyping the sample for a combination of SNPs in genes RTTN, ALCAM/CD166, and DMXL2, the SNPs comprising a G allele at SNP rs4891826 in the RTTN gene, a G allele at SNP rs2030515 in the ALCAM/CD166 gene and a C allele at SNP rs7164265 in the DMXL2 gene; and

c) detecting in said nucleic acid sample the presence of at least two of: a G for rs4891826, a G for rs2030515, or a C for rs7164265.